A new study published by CPI (one of Somnus’ chosen development partners) shows that the UK may be losing out following its early-stage investment in
Somnus CEO Dr Tim Craft has spent the last month in Australia presenting Somnus at a series of clinical and investor meetings. In this second
Somnus CEO Dr Tim Craft has spent the last month in Australia presenting Somnus at a series of clinical and investor meetings. We asked him
NHS England has recently announced that by early 2024 desflurane will no longer be usedapart from in some exceptional and rare cases. As they say
In a recent article in the New England Journal of Medicine, Professor Don Berwick of the influential Institute for Healthcare Improvement and other key senior
This is a compendium of all the latest evidence on how to make standard practice in operatingtheatres sustainable and as environmentally friendly as possible. This
Professor Mike Parr is a member of the Somnus Advisory Board and is Director of Intensive Care and Executive Clinical Director at Liverpool Hospital, Sydney,
A recent article in the BMJ examined the damage being done to the environment by the continued use of inhalation anaesthetics, which are greenhouse gases.
Richard Luxton is the Director of Biosensing Technology at the Health Tech Hub at UWE and oversees the Somnus project. Q. What is your role?
Kiely is the Co-Director of the Health Tech Hub at UWE with Richard Luxton. Where Richard’s focus is biochemistry, Janice’s is electronic engineering. This brings
Somnus is also a Scale-Up member of SETSquared.
Somnus Scientific Ltd
Stockland
Beechen Cliff Rd
Bath
BA2 4QR
